Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Avient Corporation (AVNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Avient Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $298.5 (market cap $39.89B), while Avient Corporation trades at $36.03 (market cap $3.30B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.1× Avient Corporation's market cap, and Avient Corporation pays a 3.05% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | AVNT | |
|---|---|---|
Market Cap | $39.89B | $3.30B |
Sector | Health | Technology |
52-Week High | $491.22 | $43.28 |
52-Week Low | $278.09 | $27.48 |
Enterprise Value | $38.15B | $4.80B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Avient Corporation (AVNT) trades at $36.03, showing modest daily gains of 0.14%. The stock exhibits bearish technical signals with moving averages and ADX indicators pointing downward, though RSI levels remain neutral. Fundamentally, the company maintains stable revenue around $3.3 billion with improving profitability, as evidenced by three consecutive quarterly earnings beats. Recent product launches in barrier technology and dielectric thermoplastics demonstrate innovation in materials solutions.
Avient presents a mixed investment case with strong analyst support (60% buy ratings) offset by technical weakness. The company's consistent earnings performance and dividend payments provide stability, while competitive pressures and market volatility remain key risks. Near-term catalyst includes Q2 2026 earnings release on August 6, 2026, where the company faces expectations of $0.89 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →
